Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Orphan Status Granted to GW’s Cannabis Drug

By Drug Discovery Trends Editor | April 21, 2016

​Epidiolex, a cannabis-based drug designed to treat epilepsy made by GW Pharmaceuticals, was granted orphan status by the Food and Drug Administration (FDA).

The designation was given based on the drug’s potential viability in treating a rare genetic disorder called tuberculosis sclerosis complex (TSC), which can induce epilepsy in an estimated 80 to 90 percent of patients diagnosed with it, reported Reuters. An approximate 50,000 people in the U.S. have TSC with nearly 1 million patients diagnosed with this disease worldwide based on statistics published on the TSC Alliance’s homepage.

Currently, GW is in the middle of a Phase 3 study assessing Epidiolex’s impact on this TSC.

TSC marks the third indication GW is pursuing. The firm announced last month Epidiolex successfully lowered the rate of convulsive seizures brought on by external factors like high fever in patients suffering from another rare disorder called Dravet syndrome.

Orphan drug status provides GW with incentives like seven-year marketing exclusivity and expedited reviews as it seeks to prove the therapeutic benefits of drugs derived from cannabis, but the journey to regulatory approval could have some obstacles.

The Associated Press reported earlier this week that medical marijuana activists are wary that FDA approval “will mark the beginning of Big Pharma’s takeover of the marijuana plant, undercutting patients’ ability to treat themselves as they see fit.”

GW’s stock was up 0.74 percent in early morning trading. 

R&D 100 AWARD ENTRIES NOW OPEN:

Establish your company as a technology leader! For more than 50 years, the R&D 100 Awards have showcased new products of technological significance. You can join this exclusive community!  Learn more.


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50